Preparation and in vitro tumor cells selectivity of sterically stabilized immunoliposomal peptides in bee venom.
- Author:
Hai-yang HU
1
;
Da-wei CHEN
;
Yan-fang LIU
;
Ming-xi QIAO
;
Xiu-li ZHAO
Author Information
1. School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China. haiyang_hu@hotmail.com
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
administration & dosage;
pharmacology;
Bee Venoms;
chemistry;
Carcinoma, Hepatocellular;
pathology;
Cell Line, Tumor;
Cell Survival;
drug effects;
Cholesterol;
chemistry;
Drug Delivery Systems;
HeLa Cells;
Humans;
Immunoconjugates;
chemistry;
pharmacology;
Liposomes;
chemistry;
Liver Neoplasms;
pathology;
Melitten;
administration & dosage;
isolation & purification;
pharmacology;
Peptides;
administration & dosage;
isolation & purification;
pharmacology;
Recombinant Proteins;
administration & dosage;
pharmacology
- From:
Acta Pharmaceutica Sinica
2007;42(11):1201-1205
- CountryChina
- Language:Chinese
-
Abstract:
Recently the use of peptides in bee venom (PBV) for cancer therapy has attracted considerable attention. In this study, the sterically stabilized liposomal PBV (PBV-SL) was prepared using soybean phosphatidylcholine, cholesterol, and cholesterol-PEG-COOH. The humanized antihepatoma disulfide-stabilized Fv (hdscFv25) was coupled to sterically stabilized liposomes using the N-hydroxysuccinimide ester method. The hdscFv25-immunoliposomes (SIL[hdscFv25]) were immunoreactive as determined by ELISA assay. SIL[hdscFv25] showed higher tumor cells selectivity. PBV-SIL[hdscFv25] can kill SMMC-7721 cells in vitro with higher efficiency than non-targeted liposomes. Whereas cytotoxicties were compared for Hela cells, no significant differences was observed between PBV-SIL[hdscFv25] and PBV-SL. Sterically stabilized immunoliposomal peptides in bee venom could be one drug targeting delivery system.
